Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2182)
All Articles published online
|
Dec 7, 2008 (publication date) through Apr 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v14/i45/6902.htm |
| Number | Citing Articles |
| 1 |
Sanem Karadag Gecgel. Comparison of HBV-DNA Levels with Biochemical and Microbiological Parameters for Chronic Hepatitis Evaluation, Bursa, Turkey. Journal of Medical Microbiology and Infectious Diseases 2021; 9(1): 17 doi: 10.52547/JoMMID.9.1.17
|
| 2 |
Pietro Lampertico, Mala Maini, George Papatheodoridis. Optimal management of hepatitis B virus infection – EASL Special Conference. Journal of Hepatology 2015; 63(5): 1238 doi: 10.1016/j.jhep.2015.06.026
|
| 3 |
Jiyun Fan, Ying Wang, Hui Xiong, Xiaokui Guo, Yung-chi Cheng. Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility. Journal of General Virology 2014; 95(11): 2523 doi: 10.1099/vir.0.066886-0
|
| 4 |
Qingxian Cai, Fengjuan Chen, Xiaoqiong Shao, Xiaohong Zhang, Zhixin Zhao, Zhiliang Gao. Treatment of Pegylated Interferon-α2a in Chronic Hepatitis B Patients Demonstrating a Spontaneous Decline in HBV DNA after Acute Exacerbation. Antiviral Therapy 2015; 20(2): 217 doi: 10.3851/IMP2832
|
| 5 |
Xianzheng Wang, Aihua Dong, Jingjing Xiao, Xingjun Zhou, Haili Mi, Hanqian Xu, Jiming Zhang, Bin Wang. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice. Cellular & Molecular Immunology 2016; 13(6): 850 doi: 10.1038/cmi.2015.64
|
| 6 |
Jianhua Hu, Yong Wang, Gongying Jiang, Jie Zheng, Tuxiang Chen, Zhiping Chen, Meifang Yang, Xuan Zhang, Hong Zhao, Lanjuan Li. Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infection. Journal of International Medical Research 2020; 48(11): 030006052096958 doi: 10.1177/0300060520969582
|
| 7 |
Spyros I. Siakavellas, George V. Papatheodoridis. Controversial Issues in Current Treatment of Chronic HBV Infection. Current Hepatology Reports 2015; 14(3): 164 doi: 10.1007/s11901-015-0268-4
|
| 8 |
Hui Zhang, Jianchun Xian, Yang Li, Li Xiao, Lu Wang, Muhammad Zia-Ul-Haq. Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/1889628
|
| 9 |
George V. Papatheodoridis. Hepatitis B virus treatment: Which patients can have treatment deferred?. Clinical Liver Disease 2013; 2(1): 15 doi: 10.1002/cld.160
|
| 10 |
Wen-cong Li, Mao-rong Wang, Ling-bo Kong, Wei-guang Ren, Yu-guo Zhang, Yue-min Nan. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infectious Diseases 2011; 11(1) doi: 10.1186/1471-2334-11-165
|
| 11 |
G. Papatheodoridis, V. Sypsa, M. Kantzanou, I. Nikolakopoulos, A. Hatzakis. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. Journal of Viral Hepatitis 2015; 22(4): 409 doi: 10.1111/jvh.12314
|
| 12 |
Jiannis Vlachogiannakos, George V. Papatheodoridis. Optimal therapy of chronic hepatitis B: how do I treat HBeAg‐positive patients?. Liver International 2015; 35(s1): 100 doi: 10.1111/liv.12719
|
| 13 |
EunYoung Ze, Eun Kyung Baek, Jong Jin Lee, Han Wook Chung, Dae Geon Ahn, Hwan Jun Cho, Jae Cheol Kwon, Hyung Joon Kim, HyunWoong Lee. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clinical and Molecular Hepatology 2014; 20(3): 267 doi: 10.3350/cmh.2014.20.3.267
|
| 14 |
Zhuo-Lun Song, Yu-Jun Cui, Wei-Ping Zheng, Da-Hong Teng, Hong Zheng. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World Journal of Gastroenterology 2015; 21(42): 12091-12100 doi: 10.3748/wjg.v21.i42.12091
|
| 15 |
Alexandra Alexopoulou, George V Papatheodoridis. Entecavir treatment in HBV-related decompensated cirrhosis. Future Virology 2011; 6(11): 1275 doi: 10.2217/fvl.11.103
|
| 16 |
George V. Papatheodoridis, Emmanuel Tsochatzis, Svenja Hardtke, Heiner Wedemeyer. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver International 2014; 34(10): 1452 doi: 10.1111/liv.12565
|
| 17 |
Ting-Tsung Chang. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatology International 2009; 3(S1): 16 doi: 10.1007/s12072-009-9143-0
|
| 18 |
Munira Jahan, Shahina Tabassum, Mamun Al-Mahtab, Afzalun Nessa, Chowdhury Mohammad Shamim Kabir, Mohammad Kamal, Julio Cesar Aguilar. Hepatitis B Core Antigen in Hepatocytes of Chronic
Hepatitis B: Comparison between Indirect
Immunofluorescence and Immunoperoxidase Method. Euroasian Journal of Hepato-Gastroenterology 2015; 5(1): 7 doi: 10.5005/jp-journals-10018-1120
|
| 19 |
Jiannis Vlachogiannakos, George V. Papatheodoridis. HBV: Do I treat my immunotolerant patients?. Liver International 2016; 36(S1): 93 doi: 10.1111/liv.12996
|
| 20 |
Melissa A. Cobleigh, Xin Wei, Michael D. Robek. A Vesicular Stomatitis Virus-Based Therapeutic Vaccine Generates a Functional CD8 T Cell Response to Hepatitis B Virus in Transgenic Mice. Journal of Virology 2013; 87(5): 2969 doi: 10.1128/JVI.02111-12
|
| 21 |
Aslı Ormeci, Yucel Aydın, Abdullah Sumnu, Bulent Baran, Ozlem Mutluay Soyer, Binnur Pınarbasi, Suut Gokturk, Mine Gulluoglu, Derya Onel, Selim Badur, Filiz Akyuz, Cetin Karaca, Kadir Demir, Fatih Besisik, Sabahattin Kaymakoglu. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. International Journal of Infectious Diseases 2016; 52: 68 doi: 10.1016/j.ijid.2016.09.007
|
| 22 |
Zhengyan Wang, Ling Sun, Yuwan Wu, Qing Xia. Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2016; 40(2): 195 doi: 10.1016/j.clinre.2015.06.022
|
| 23 |
Valter Oberdan Borges de OLIVEIRA, Juliana Passos Rocha OLIVEIRA, Eloy Vianey Carvalho de FRANÇA, Hugo Leite de Farias BRITO, Tereza Virgínia NASCIMENTO, Alex FRANÇA. ADVANCED LIVER INJURY IN PATIENTS WITH CHRONIC HEPATITIS B AND VIRAL LOAD BELOW 2,000 IU/mL. Revista do Instituto de Medicina Tropical de São Paulo 2016; 58(0) doi: 10.1590/S1678-9946201658065
|
| 24 |
Steven-Huy Han, Wuhua Jing, Edward Mena, Michael Li, Brett Pinsky, Hong Tang, Tony Hebden, Timothy Juday. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy. Journal of Medical Economics 2012; 15(6): 1159 doi: 10.3111/13696998.2012.710690
|